Later in 2012, Arslan et al. reported the first humanized anti-TLR2 antibody, OPN-305, which reduced infarct size, preserved systolic function and eventually prevented myocardial damage in a pig model of Ischemia/Reperfusion Injury [93,94]. This evidence concerns the gene TLR2 and ischemia.